UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
 
 

FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): January 22, 2016
 
 
 

STRYKER CORPORATION
(Exact name of registrant as specified in its charter)
 
 
 
 
Michigan
(State or other jurisdiction
of incorporation)
0-9165
(Commission
File Number)
38-1239739
(IRS Employer
Identification No.)
 
 
 
2825 Airview Boulevard, Kalamazoo, Michigan
(Address of principal executive offices)
49002
(Zip Code)
 
 
 
Registrant's telephone number, including area code: 269.385.2600

 
 
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
 
 
[ ]
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)




 
 
[ ]
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
 
[ ]
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
 
[ ]
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))






 
 
 
Item 5.02
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

Stryker Corporation announced on January 26, 2016 that William R. Jellison has decided to retire from his role as Vice President, Chief Financial Officer effective April 1, 2016 and that Glenn Boehnlein, who currently serves as Group Vice President, Chief Financial Officer for Med Surg & Neurotechnology, has been promoted to Vice President, Chief Financial Officer effective April 1.

Mr. Jellison has entered into a Transition Agreement with the Company pursuant to which he will continue to be employed as an Advisor to the Chief Financial Officer from April 1, 2016 through March 31, 2017 to ensure a smooth transition. During the advisory period, Mr. Jellison will continue to receive base salary at his current annual rate of $554,000 and will be entitled to receive an advisory period incentive bonus in the amount of $387,800 provided he remains employed in the advisory capacity through December 31, 2016 and an additional $150,000 if he continues through the conclusion of the advisory period on March 31, 2017. Pursuant to the terms of the plans and award agreements under which he has been granted stock options, restricted stock units and performance stock units, any unvested grants will lapse when his employment terminates and stock options that are vested on that date will lapse unless exercised within 30 days thereafter.

Pursuant to the letter agreement establishing Mr. Boehnlein’s compensation in his new role, Mr. Boehnlein will receive a base salary at the annual rate of $550,000. Mr. Boehnlein’s bonus potential will be 80% of his annual salary. His actual bonus will be prorated based on the portion of the year that he serves as Vice President, Chief Financial Officer and will be determined based on performance against objectives to be developed with the Company’s Chairman and Chief Executive Officer. The letter agreement also provides that the Company’s Chairman and Chief Executive Officer will recommend that



the Board of Directors and Compensation Committee approve the award to him of stock options and performance stock units having a grant date fair value of $1,900,000, comprised of 50% in stock options and 50% in performance stock units, on the regular annual equity award grant date in February 2016. Mr. Boehnlein will be eligible to receive benefits in accordance with the Company’s US Domestic Mobility Program with respect to his relocation to the Company’s headquarters in Kalamazoo, Michigan, including a lump sum payment of $18,000, and the other benefits generally available to the members of the Company’s executive leadership team

The summary descriptions of the Transition Agreement with Mr. Jellison and the letter Agreement with Mr. Boehnlein contained in this Form 8-K are not complete and are qualified in their entirety by, and should be read in conjunction with, the complete text of such agreements that are filed as Exhibit 10.1 and 10.2, respectively, to this Form 8-K and are incorporated herein by reference.


 
 
 
Item 9.01
Financial Statements and Exhibits.
 
 
 
(d)
Exhibits
 
10.1 Transition Agreement between Stryker Corporation and William R. Jellison.
10.2 Letter Agreement between Stryker Corporation and Glenn Boehnlein
 
99.1  Press Release dated January 26, 2016.


SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 
 
 
 
 
 
STRYKER CORPORATION
 
 
(Registrant)
 
 
 
 
 
 
January 26, 2016
 
/s/ DEAN H. BERGY
Date
 
Dean H. Bergy,
Vice President, Corporate Secretary
 




Exhibit 10.1

TRANSITION AGREEMENT

‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬ ‬‬
‬‬This Transition Agreement (“ Agreement ”) is entered into as of January 26th, 2016 by William Jellison (“ Employee ”) and Stryker Corporation, a Michigan corporation, with a place of business at 2825 Airview Blvd. Kalamazoo, Michigan 49002 (hereinafter referred to as “Stryker ”). As used in the Agreement, “ Stryker ” or “ the Company ” shall include Stryker, its subsidiaries and divisions, and their present and past directors, officers, employees, agents, and representatives.‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬ ‬‬
Employee presently holds the position of Vice President, Chief Financial Officer. Employee has stated his intention to retire from his role, and this Agreement sets forth the terms of his transitional role and subsequent retirement from Stryker.
In consideration of the mutual promises and undertakings of the parties, it is hereby agreed as follows:
1.
Ongoing Employment and Termination.
   
(a) Transition from Current Role to New Role . Employee’s role as Vice President, Chief Financial Officer will terminate effective April 1, 2016. In addition, any ongoing signing authority on behalf of Stryker will be revoked as of that date. If Employee accepts the compensation and benefits outlined in Paragraph 2 he will serve as an Advisor to Chief Financial Officer, from April 1, 2016 through March 31, 2017 (the “Advisory Period”).

(b) Responsibilities during Advisory Period . During the Advisory Period, Employee will (a) provide advice and information related to the CFO transition process, including, but not limited to finalizing the first quarter 2016 financials; (b) serving as a key advisor to the CFO of Stryker with regard to various financial matters; (c) engaging in projects as assigned by the Chief Financial Officer of Stryker; and (d) otherwise cooperating and performing duties and responsibilities as assigned by the CFO or a designee. Employee will comply with all company policies during this period of employment with Stryker.
    
(c) Termination of Employment . Employee’s employment with Stryker shall terminate in any capacity or position effective March 31, 2017 (the “ Termination Date ”). If Employee resigns or finds alternate employment outside of Stryker prior to March 31, 2017, this date will be considered his Termination Date. Except as expressly provided in paragraph 2 , below, Employee’s entitlement to compensation, benefits, damages, costs, expenses or monetary amounts of any kind from Stryker will cease as of the Termination Date.‬‬

2. Ongoing Compensation and Benefits.
    
(a) Ongoing Compensation. In exchange for the promises made by Employee in this Agreement, Stryker agrees to continue to pay Employee his current base semi-monthly salary compensation in effect as of the date of this Agreement in the amount of $23,083.33 per semi-monthly pay period from April 1, 2016 through the Termination Date. Such payments are subject to appropriate federal, state and local withholding taxes.

(b)      Compensation - Incentive Pay and Future Payments. Employee will receive payment of his 2015 year-end incentive bonus in accordance with its terms at the time such payments are made to other comparable employees. Employee will be eligible to receive a 2016 year-end Advisory Period incentive bonus in the amount of $387,800 provided that he remains employed as an advisor to Stryker through December 31, 2016. The bonus will be paid at the time such payments are made to other comparable employees. As further consideration, Employee will be eligible to receive a 2017 Advisory Period incentive bonus in the amount of $150,000, conditioned on continued performance through the conclusion of the Advisory Period. If earned, this payment





shall be made no later than April 30, 2017.
(c)      Compensation - Incidentals. Stryker will reimburse Employee for all appropriate incidental travel and business expenses related to the Employee’s employment through the Termination Date consistent with Stryker’s policies, as presently constituted or as amended, provided that all expense reports are submitted to Glenn Boehnlein for reimbursement on or before March 31, 2017.
(d)      Vacation Pay. Employee will be entitled to use vacation time accrued through the Termination Date. Stryker will not pay out any unused vacation after the Termination Date.
(e)      COBRA. After termination of employment, Employee has the right to receive COBRA provided that Employee elects COBRA and Employee pays for the cost of COBRA. COBRA continuation coverage may be terminated if Employee does not timely pay Employee’s portion of the required monthly cost of coverage. Stryker reserves the right at any time to alter, modify, amend or terminate its health benefits and plan documents in any manner it deems appropriate and all such changes shall be applicable to Employee.‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬
(f)      Equity Awards. Employee currently holds Restricted Stock Units (“RSUs”), Performance Stock Units (“PSUs”) options to purchase Stryker Common Stock (“ Stock Options ”) that are described, as to grant date, number of shares covered, purchase price, and vesting schedule, on Exhibit B hereto (collectively, the “ Equity Awards ”). Each such Equity Award shall remain exercisable in accordance with its original terms. With respect to any outstanding Equity Award, Employee acknowledges that Employee will cease to be an employee on the Termination Date and that accordingly, pursuant to the terms of the long term incentive plan(s) and/or Award Agreements under which they were granted, as of the Termination Date (i) any unvested Equity Award will lapse, and (ii) any Stock Options that have vested as of that date will lapse unless exercised within thirty (30) days after such date according to the terms of such plans. ‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬ ‬‬
3. Personnel Records. Employee’s permanent personnel record at Stryker will reflect the Employee’s termination of employment with Stryker effective as of the Termination Date.

4. Reference. The parties agree that as to any person or entity that seeks an employment reference for Employee, Stryker will only offer the following information: positions held, dates of employment, and salaries earned unless Employee provides a written release to Stryker authorizing the provision of additional information.

5. Release. In exchange for the compensation and benefits to be provided by Stryker, Employee, for the Employee and for the Employee’s heirs, personal representatives, successors and assigns, hereby:

(a)      releases and forever discharges Stryker from all claims, causes of action, demands, rights, damages, liability, costs or expenses, of every kind and description, whether known or unknown, which the Employee now has or has ever had in the past, of every nature or cause, arising out of or in any way connected, directly or indirectly, with Employee’s employment with Stryker or the termination of that employment. This release includes, but is not limited to, claims of discrimination based on age, race, color, national origin, ancestry, religion, marital status, sex, citizenship status, medical condition or disability, height, weight, or any other legally protected characteristic or preference; claims of sexual, racial, religious or other harassment; breach of implied or express contract, including the covenant of good faith and fair dealing; any claim for back wages, bonus payments, or other compensation or benefits; intentional interference with contractual relations or prospective economic advantage; negligent or intentional misrepresentation; negligence; fraud; estoppel or reliance; defamation, slander, or libel; negligent and intentional infliction of emotional distress; violation of public policy; wrongful or constructive discharge; invasion of privacy; any claim under applicable state and local wage and hour laws; violation of the Worker Adjustment and Retraining Notification Act; any claim for severance under the Stryker Corporation Discretionary Severance Pay Plan, and any claim of any type whatsoever, whether based on contract or tort, or any federal, state or local statute, regulation, rule or ordinance, including, but not limited to, the Age Discrimination in Employment Act, as amended, Title VII of the Civil Rights Act of 1964 as amended, the Civil Rights Act of 1870, the Genetic Information Nondiscrimination Act of 2008, the Occupational Safety and Health Act of 1970, the Americans with Disabilities Act of 1990, as





amended, the Older Workers Benefit Protection Act of 1990, the Equal Pay Act of 1963, the Family and Medical Leave Act, the Employee Retirement Income Security Act of 1974 (“ ERISA ”), to the extent provided by law, the Civil Rights Act of 1991, the Sarbanes-Oxley Act of 2002, the Michigan Elliott-Larsen Civil Rights Act, and the Michigan Handicappers’ Civil Rights Act, and any analogous state or local law in the state in which Employee works. Employee reserves any rights the Employee may have to claim workers’ compensation, unemployment compensation, COBRA benefits, and other vested benefits. Employee waives any procedural requirements or rights created by any bylaws, personnel policies, benefit statements or summaries, or contracts of employment (written or unwritten), except as set forth in this Agreement. As used in this paragraph and paragraph 6 , “ Stryker ” shall describe collectively Stryker Corporation and its affiliates, subsidiaries, divisions, parent and sister companies, trustees, officers, divisions, shareholders, representatives, agents, employees, attorneys, successors, assigns, and any employee benefit plan or funds established, sponsored or administered by any of them. Employee acknowledges and agrees that in consideration for the benefits and compensation provided herein, the Employee is not eligible for and will not receive any payments under the Stryker Corporation Discretionary Severance Pay Plan.‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬ ‬‬
6. Other Claims or Lawsuits. Employee shall not institute any lawsuit, claim, complaint or other proceeding against or involving Stryker based on Employee’s employment with Stryker or upon any act or omission occurring up to and including the date this Agreement is fully executed, whether as an individual or class action, with any administrative agency, regulatory agency, judicial or other forum under any federal, state or local laws, rules, regulations or any other basis. Further, Employee shall not seek or accept any award or settlement from any such source or proceeding (not including unemployment insurance proceedings). In the event that Employee institutes, is a knowing participant, or is a willing member of a class that institutes any such action, the Employee’s claims shall be dismissed or class membership terminated with prejudice immediately upon presentation of this Agreement. This Agreement does not prohibit Employee from participating in an investigation by the Equal Employment Opportunity Commission or any analogous state agency, but the Employee acknowledges that the Employee is not entitled to any other monies other than those described in this Agreement and that if the Employee ever makes and/or files any claim and/or, cause of action against Stryker, the Employee will withdraw it with prejudice within seven (7) days and, if requested, stipulate to court and/or agency approval and enforcement of this Agreement.

7. Trade Secrets and Confidential and Proprietary Information. Employee agrees that, except as may otherwise be required by law, the Employee will at no time disclose to any third party, nor use for the Employee’s own benefit or for the benefit of any third party, any trade secrets, confidential information or proprietary information concerning the financial and business affairs of Stryker. “ Confidential and proprietary information ” includes, but is not limited to, know-how, trade secrets, and technical, business and financial information and any other non-public information in any way learned by the Employee during the Employee’s employment with Stryker, including, but not limited to (a) prices, renewal dates and other detailed terms of customer or supplier contracts and proposals; (b) information concerning Stryker’s customers, clients, referral sources and vendors, and potential customers, clients, referral sources and vendors, including, but not limited to, names of these entities or their employees or representatives, preferences, needs or requirements, purchasing or sales histories, or other customer or client-specific information; (c) supplier and distributor lists; (d) pricing policies, methods of delivering services and products, and marketing and sales plans or strategies; (e) products, product know-how, product technology and product development strategies and plans; (f) employees, personnel or payroll records or information; (g) forecasts, budgets and other non-public financial information; (h) expansion plans, management policies and other business strategies; (i) inventions, research, development, manufacturing, purchasing, finance processes, technologies, machines, computer software, computer hardware, automated systems, engineering, marketing, merchandising, and selling; and (j) any information whatsoever about the business and practices of Stryker that was obtained by him during the course of the Employee’s employment with Stryker. Employee agrees that the Employee shall not retain any documents or information concerning Stryker and will return any and all such documents and information directly to Stryker no later than the Termination Date.

8. Stryker Property. On or before March 31, 2017, Employee will return to Stryker any and all property in the Employee’s possession which belongs to Stryker, including the following: all keys and security and credit cards; all strategic plans, budget books, and other financial, planning, marketing, strategic, and product development





documents; all equipment, products, samples, inventory, tools, computers, and software; all customer files, customer lists account files, price lists, product information, and training manuals; all information relating to the performance and employment of Stryker employees; financial information in any form; and all other documents relating to Stryker’s business, products, personnel, and customers.

9. Communications. Employee agrees that, at all times, the Employee will refrain from taking any actions or making any statements, oral or written, which have the purpose or effect of injuring or in any way detracting from the reputations of Stryker, its parent company, subsidiaries and divisions, and their present and former divisions, officers, and employees or causing any person or entity to refrain from or cease any employment or business relationship with Stryker, its parent company, subsidiaries and divisions. Stryker agrees that, except as prohibited by law, it will refrain from taking any actions or making any statements, which have the purpose or effect of injuring or in any way detracting from the reputation of Employee.

10. Non-Competition. Employee acknowledges and affirms the obligations set forth in the Stryker Confidentiality, Intellectual Property, Non-Competition and Non-Solicitation Agreement that Employee signed on December 13, 2013, a copy of which is attached as Exhibit A (“Non-Compete Agreement”) and agrees that the receipt of the compensation provided under this Agreement is additional consideration for the post-termination obligations and particularly for entering into the non-competition provisions of the Non-Compete Agreement. Employee understands and agrees that the payments and benefits set forth in paragraph 2 are subject to the Employee’s full compliance with the commitments and obligations in this Agreement and the Non-Compete Agreement, and that Employee is not entitled to any other payments in order to enforce the restrictions in the Non-Compete Agreement. Employee understands and agrees that Stryker may collect from him, and that the Employee must forfeit to Stryker, the payments identified in paragraph 2 if the Employee fails to comply with the commitments and obligations as set forth in this Agreement.‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬ ‬‬

11. No Admission of Liability. The parties agree that nothing contained in this Agreement and no actions taken by either party with respect to this Agreement shall be construed as an admission by either party of any liability or obligation, all such liability or obligation being expressly denied.

12. Acknowledgments. Employee expressly acknowledges the following:
‫‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬
(a) This Agreement provides for the release by Employee of any claim that Employee may have under the Age Discrimination in Employment Act, as amended, 29 U.S.C. 621 et seq. along with the release of other claims that Employee may have as described and agreed in paragraphs 5 and 6 of this Agreement.
 
(b) Employee is hereby advised in writing to consult with an attorney before signing this Agreement.
‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬
(c) Certain of the payments and benefits to be provided to Employee under this Agreement are payments and benefits to which the Employee would not otherwise have been entitled if the Employee did not enter into this Agreement.
‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬ ‬‬
(d) Employee affirms that, other than the payments made through this Agreement, the Employee has reported all hours worked, if applicable, as of the date of this Agreement and that the Employee has been paid and/or has received all leave (paid or unpaid), compensation, wages, bonuses, commissions, and/or benefits to which the Employee may be entitled. Employee further affirms that the Employee has no known workplace injuries or occupational diseases, has been provided and/or has not been denied any leave or reasonable accommodation under applicable disability or leave laws, and has faced no reprisal for exercising the Employee's right to any leave and/or reasonable accommodation.
‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬ ‬‬
13. Review and Consultation. Employee and Stryker acknowledge that they have each had sufficient opportunity to review the terms of this Agreement and to consult with advisors and attorneys of their choice concerning its terms and conditions. Employee acknowledges that the Employee fully and completely understands the terms of this Agreement and their significance, and that the Employee accepts those terms and enters into this Agreement freely and voluntarily thereby binding the Employee, the Employee’s heirs, successors, personal





representatives and assigns. Employee warrants that the Employee is fully competent to enter into this Agreement. and the Employee acknowledges that the Employee has been afforded the opportunity to review this Agreement with the Employee’s attorney for at least twenty-one (21) calendar days and that the Employee has consulted with the Employee’s attorney prior to executing this Agreement, that the Employee has read and understands this Agreement and enters into it freely and voluntarily. Further, Employee acknowledges that the Employee may revoke this Agreement within seven (7) days of signing it and that the Employee must return any amount received hereunder in such event. Such notice of revocation must be provided to Katy Fink, Vice President, Global Human Resources, 2825 Airview Blvd., Kalamazoo, Michigan 49002 in writing and state “I hereby revoke the Agreement.” Employee further understands that seven (7) days after execution of this Agreement, this Agreement will become effective and enforceable without any further action by Employee or Stryker.

14. Indemnification. The parties agree that the terms of the indemnification provisions applicable during Employee’s employment with Stryker shall continue in effect in accordance with their terms during the Advisory Period, through and until the Termination Date. To the extent that Employee requests indemnification for a claim that arises based upon Employee’s actions during the Advisory Period, and such indemnification requires approval, authorization or consent of Stryker’s Board of Directors, Stryker agrees to seek a Board determination within thirty (30) calendar days of Employee’s request for indemnification.

15. Continuing Cooperation. Employee agrees that up to and following the Employee’s termination of employment with Stryker, the Employee will cooperate with and assist Stryker in the resolution of corporate structure issues; employment and other legal claims and lawsuits; internal and external investigations of Stryker and its employees; any inquiry or investigation by any governmental entity; and other workplace issues concerning which Employee has knowledge. Cooperation will include at a minimum, but not be limited to, additional interviews with Stryker internal and outside counsel both before the termination of the Employee’s employment and a reasonable number of follow up interviews following the termination of the Employee’s employment, assistance with any lawsuits or claims brought against Stryker or investigations of Stryker by any person or entity or any past, present, or future Stryker employee, any lawsuit or claim brought on behalf of Stryker, any requests to prepare or execute materials related to the organizational structure of Stryker Corporation and its affiliated entities and/or assisting Stryker in any response to government inquiries and document requests. Employee further agrees that the Employee will notify Stryker promptly if the Employee is contacted by any third party, including any government agency, concerning any potential claim against Stryker or any investigation of Stryker's current or historical conduct. Nothing in this agreement restricts the ability of Employee to provide information in response to an official government inquiry concerning Stryker or to report possible violations of federal law or regulation to the government, provided that Employee will not disclose information to any party that is protected by the attorney-client privilege or the attorney work product doctrine.

16. Section 409A. The intent of the parties is that payments and benefits under this Agreement either comply with Section 409A or be exempt from the application of Section 409A and, accordingly, to the maximum extent permitted, this Agreement shall be interpreted to be in compliance therewith. To the extent that any provision hereof is modified in order to comply with Section 409A, such modification shall be made in good faith and shall, to the maximum extent reasonably possible, maintain the original intent and economic benefit to Employee and Stryker of the applicable provision without violating the provisions of Section 409A. Employee’s Termination Date is intended to be the date as of which he incurs a “separation from service” for purposes of Section 409A.

17. Attorney’s Fees. Other than as provided within paragraph 16 , nothing contained herein shall be interpreted to render any party a prevailing party for any reason, including but not limited to an award of costs or attorney's fees.

18. Choice of Law, Forum Selection, and Remedies. This Agreement shall in all respects be governed by the laws of the State of Michigan. Any legal action or claim relating to the terms of this Agreement shall be filed, heard and decided exclusively in the state courts in Kalamazoo County, Michigan, or the U.S. District Court for the Western District of Michigan (the “ Courts ”) and the parties hereby consent to the personal jurisdiction and venue of the Courts. The parties further agree that: (a) any breach or threatened breach of paragraph 7 (Trade Secrets and





Confidential and Proprietary Information), paragraph 8 (Stryker Property), paragraph 9 (Communications), and paragraph 10 (Non-Solicitation) of this Agreement would cause irreparable harm to Stryker; (b) a remedy at law or in damages would be inadequate to remedy such a breach or threatened breach; (c) the provisions of paragraphs 7, 8, 9 and 10 of this Agreement may be enforced by way of a restraining order or injunction, in addition to any other remedies which may be available by law; and (d) the non-prevailing party in any action to enforce these provisions shall be liable for the reasonable attorney’s fees and costs incurred by the prevailing party.

19. Severability. All agreements and covenants set forth within this Agreement are severable. In the event any of them shall be held to be invalid by any competent court, this Agreement shall be interpreted as if such invalid agreement or covenant were not contained within this Agreement and such invalid agreement or covenant shall be interpreted and applied so that it is enforceable to the fullest extent allowable by law.

20. Confidentiality. The parties shall keep the terms and provisions of this Agreement confidential, and shall not disclose or discuss any of the terms of this Agreement to or with other persons or entities except as required by law or in order to enforce the terms of this Agreement, and, as to Employee, to the Employee’s counsel, family, and tax and financial planning advisors.

21. Entire Agreement. With the exception of the Non-Compete Agreement attached as Exhibit A , this Agreement contains the entire understanding of the parties, and there are no additional promises, representations, assurances, terms or provisions between the parties. This Agreement may not be amended except in writing signed by Employee and a duly authorized officer of Company.

 
 
 
 
 
 
Stryker Corporation
 
 
 
 
 
 
 
Signature:
 
/s/ WILLIAM R. JELLISON
 
Signature:
 
/s/ KATY FINK
 
 
 
 
 
 
 
Date:
 
January 26, 2016
 
Name:
 
Katy Fink
 
 
 
 
 
 
 
 
 
 
 
Title:
 
Vice President, Global Human Resources
 
 
 
 
 
 
 
 
 
 
 
Date:
 
January 26, 2016


EXHIBIT A
Non-Compete Agreement

EXHIBIT B
Stock Grants



Exhibit 10.2

2825 Airview Boulevard
Kalamazoo, Michigan 49002

January 23, 2016

Glenn S. Boehnlein
Stryker
5900 Optical Court
San Jose, California 95138


Dear Glenn,

It is with pleasure that I confirm your promotion to Vice President, Chief Financial Officer, reporting to Kevin Lobo, Chairman and CEO. The role will be based in Kalamazoo, Michigan.
The effective date of this change is April 1, 2016. Your salary will be at the rate of $22,916.67 paid semi-monthly ($550,000.00 annualized figure). Applicable payroll deductions as required by State and Federal law will be withheld from your paycheck, along with any voluntary deductions that you authorize.
You will be eligible for a performance bonus for the year 2016. Your 2016 bonus potential is 80% of your annual salary, prorated based on the effective date of this position change, and is based upon performance to specific objectives for the year. You and your manager will develop your objectives together soon after you begin your new role. Bonuses are paid in February following the respective bonus year period. Any award above the 100% potential is at the Company’s discretion, and you must be employed on December 31 of each year to receive any portion of this bonus.
You are scheduled to receive a performance review in February 2017, and you are eligible for a merit increase in March 2017 based upon your performance. Subsequent reviews will be conducted on an annual basis.
In addition, Stryker’s Chairman and CEO will recommend that our Compensation Committee and Board of Directors approve an award to you of stock options and performance stock units (PSUs) under Stryker’s Long-Term Incentive Plan in February 2016. The target amount granted to you under this recommendation will be approximately $1,900,000 in total grant date fair value, comprised of 50% in stock options and 50% in PSUs.  Stryker determines grant date fair value for stock options as the number of options times the grant price times a recent accounting valuation of option grants (recently averaging about 20% of the amount resulting from multiplying the number of options times the grant price). PSUs grant date fair value is calculated as the number of units times the grant price. The grant price will be the closing price on the trading day prior to the grant date(s) as required by Stryker’s Long-Term Incentive Plan. Under this recommendation, stock options would have a ten-year term and vest as to 20% of the underlying shares on each of the first five anniversary dates of the grant date. Vesting of any PSUs occurs on March 21 of the year following the three-year performance cycle with the amount of shares earned subject to the achievement of pre-established performance goals.  Any outstanding stock awards you have at the time of termination will be subject to the terms and conditions of Stryker’s Long-Term Incentive Plans, as amended from time to time by the Company.




You are also eligible to receive relocation benefits in accordance with the company’s US Domestic Mobility Program #5 that will include in addition to other relocation benefits, a lump sum in the amount of $18,000.  A summary of these relocation benefits are included within your offer package and are intended for your relocation to the Kalamazoo, Michigan area in 2017. You will be contacted by NEI, Stryker’s relocation partner, to provide you with a high level overview of your benefits eligibility.  Please note that initiating your relocation process and services is contingent upon your signing and returning a Relocation Repayment Agreement that will be provided to you by NEI.
As you have already received Stryker’s Employee Handbook, you understand that by accepting this position, you agree to abide by the guidelines set forth in the Handbook, as well as any changes to it, which may be communicated verbally or in writing. You also acknowledge that you are aware of Stryker’s at-will employment relationship with you.
To accept this offer, please sign this letter on the space below, and return it to me by January 26, 2016.
Congratulations on your new role!
Sincerely,
/s/ KATY FINK
Katy Fink
Vice President, Global Human Resources


I accept this offer of employment with Stryker and agree to the terms and conditions outlined in this letter:

/s/ GLENN S. BOEHNLEIN                       01/25/2016
Glenn S. Boehnlein                          Date

Encl:    US Domestic Mobility Policy Summary Document Program 5

c:     Employee file
Kevin Lobo
        




Exhibit 99.1

Stryker Announces the Retirement of William R. Jellison and the promotion of
Glenn S. Boehnlein to Vice President, Chief Financial Officer

Kalamazoo, Michigan - January 26, 2016 - Stryker Corporation (NYSE: SYK) announced today that William R. Jellison will retire from his role as Vice President, Chief Financial Officer. Bill’s decision follows an impressive 36 year career, the last three of which have been with Stryker. Bill will pursue his interests of becoming more involved with board roles, having recently joined the board of PolyOne Corporation, and devoting more time to his family. He will remain as CFO through the first quarter of 2016 to ensure a smooth transition. Glenn S. Boehnlein, who currently serves as Group CFO for MedSurg & Neurotechnology (MSNT), will assume the role of Vice President, Chief Financial Officer effective April 1, 2016.

“I want to thank Bill for his leadership since joining Stryker as he helped advance a series of key priorities, including implementing a layered hedging program, executing on a number of acquisitions, and facilitating the establishment of our European regional headquarters,” stated Kevin A. Lobo, Chairman and Chief Executive Officer. “These accomplishments have meaningfully contributed to our success and were achieved while enabling our internal talent pool to develop, including Glenn who has been promoted to CFO. I am confident in Glenn’s ability to lead our finance organization and partner with the broader organization to help Stryker continue to deliver sales growth at the high end of Med Tech while consistently achieving leveraged earnings gains.”

Glenn joined Stryker in 2003 as the Vice President of Finance and IT for Stryker’s Endoscopy division and has taken on roles of increasing responsibility, including his current role as Group CFO of MSNT, which he assumed in 2011. He has a strong and established track record and will continue to uphold the financial standards and practices that enable Stryker’s growth. Glenn’s career began with achieving a CPA degree and rising to Partner at Arthur Andersen, where he worked with large private and public companies, including private offerings and M&A transaction consulting. He then spent three years with Success TV as the company’s CFO prior to joining Stryker. Glenn received his Bachelors and Masters in Accounting from Mississippi State University.

About Stryker

Stryker is one of the world's leading medical technology companies and, together with our customers, we are driven to make healthcare better. The Company offers a diverse array of innovative products and services in Orthopaedics, Medical and Surgical, and Neurotechnology and Spine that help improve patient and hospital outcomes. Stryker is active in over 100 countries around the world.  Please contact us for more information at www.stryker.com.

Contacts

For media inquiries please contact:
Yin Becker, Stryker Corporation, 269-385-2600 or yin.becker@stryker.com

For investor inquiries please contact:
Katherine A. Owen, Stryker Corporation, 269-385-2600 or katherine.owen@stryker.com

Forward Looking Statements

This press release contains information that includes or is based on forward-looking statements within the meaning of the federal securities law that are subject to various risks and uncertainties that could cause our actual results to differ materially from those expressed or implied in such statements. Such factors include, but are not limited to: weakening of economic conditions that could adversely affect the level of demand for our products; pricing pressures generally, including cost-containment measures that could adversely affect the price of or demand for our products; changes in foreign exchange markets; legislative and regulatory actions; unanticipated issues arising in connection with clinical studies and otherwise that affect U.S. Food and Drug Administration approval of new





products; changes in reimbursement levels from third-party payors; a significant increase in product liability claims; the ultimate total cost with respect to the Rejuvenate and ABG II matter; the impact of investigative and legal proceedings and compliance risks; resolution of tax audits; the impact of the federal legislation to reform the United States healthcare system; changes in financial markets; changes in the competitive environment; our ability to integrate acquisitions; and our ability to realize anticipated cost savings as a result of workforce reductions and other restructuring activities. Additional information concerning these and other factors is contained in our filings with the U.S. Securities and Exchange Commission, including our Annual Report on Form 10-K and Quarterly Reports on Form 10-Q.